Researchers at The Ohio State University have discovered that middle-aged smokers have a higher likelihood of experiencing confusion and memory loss in comparison to their nonsmoking counterparts. The study, which is the first to look into the link between cognitive decline and smoking, has also found that the likelihood of cognitive decline is lower in individuals who stopped smoking.
The researchers were also focused on determining whether this link was modified by gender at birth. Their findings build on prior studies that established links between smoking and forms of dementia such as Alzheimer’s disease.
For their study, the researchers used data from the Behavioral Risk Factor Surveillance System. The survey, which was conducted in 2019, involved asking individuals if they had experienced more frequent or worsening memory loss and/or confusion as current or former smokers. The researchers’ analysis included 136,018 individuals and involved comparing measures of subjective cognitive decline for recent former smokers, current smokers and persons who had stopped smoking years earlier.
They observed that the prevalence of subjective cognitive decline among individuals who had stopped smoking less than a decade ago was 1.5 times that of nonsmokers while the prevalence of the same among current smokers was almost two times that of the nonsmoking group. This was is in addition to observing that individuals who stopped smoking over 10 years prior to the survey had a prevalence that was slightly above that of the nonsmokers.
The lead author of the study, Jenna Rajczyk, stated that the group’s findings could help identify signs of trouble earlier and explained that quitting smoking would help preserve neurological health, in addition to reducing an individual’s risk for various cardiovascular and respiratory conditions. In addition, Rajczyk noted that assessing for subjective cognitive decline could be done routinely and at younger ages than cognitive decline typically begun. She added that most individuals didn’t have access to specialists or in-depth screenings, which made the potential applications for measuring subjective cognitive decline even greater.
Assistant professor of epidemiology Jeffrey Wing added that the link the researchers had observed was most significant in individuals aged between 45 to 59, which suggested that quitting smoking at this age could greatly benefit cognitive health. Wing was the senior author of the study. Furthermore, Wing highlighted that it was crucial to note that self-reported experiences didn’t confirm that an individual was experiencing decline not usual in the normal aging process and neither did they amount to diagnoses.
The study’s findings were reported in the “Journal of Alzheimer’s Disease.”
For patients showing advanced symptoms of cognitive decline, such as dementia, a number of technologies such as the health monitoring devices made by MetAlert Inc. (OTC: MLRT) can be of great help to the caregivers watching over their affected loved ones.
NOTE TO INVESTORS: The latest news and updates relating to MetAlert Inc. (OTC: MLRT) are available in the company’s newsroom at https://ibn.fm/MLRT
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase…
A team of scientists from Texas Children’s Hospital, University of Pittsburgh and Baylor College of Medicine…
In the life sciences industry, a robust pipeline is widely recognized as a critical driver…
Cardiovascular disease remains the leading cause of death in the United States, representing a significant…
Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance…
Researchers seeking new ways of fighting cancer using immunotherapy have discovered a “hidden brake” that…